Pasithea Therapeutics Corp. (NASDAQ:KTTA) Short Interest Update

Pasithea Therapeutics Corp. (NASDAQ:KTTA) was the recipient of a significant increase in short interest in January. As of January 15th, there was short interest totalling 25,800 shares, an increase of 37.2% from the December 31st total of 18,800 shares. Currently, 2.5% of the company’s shares are short sold. Based on an average trading volume of 40,700 shares, the short-interest ratio is currently 0.6 days.

Pasithea Therapeutics Stock Down 0.4 %

NASDAQ KTTA opened at $2.24 on Friday. Pasithea Therapeutics has a one year low of $2.19 and a one year high of $9.25. The stock’s 50-day moving average is $2.72 and its 200-day moving average is $3.88.

Pasithea Therapeutics Company Profile

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications.